Ingen internetforbindelse — viser den gemte version af siden.

Bristol-Myers Squ…

USUSD
← Til Screeneren

Bristol-Myers Squibb Company (LSE:0R1F) — Drug Manufacturers - General. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
bms.com
Investorrelationer
bms.com/investors.html
Sektor
Healthcare · Drug Manufacturers - General
Hovedkontor
PRINCETON, United States
Administrerende Direktør
Christopher S. Boerner
Ansatte
32 500
Grundlagt
1989
Udestående Aktier
2.04 mia. pr. 2026-07-22
Free Float
2.04 mia.
Markedsværdi
128.41 mia. USD
Insidere
0.1%
Institutionelle Investorer
84.87%
Branche (SIC)
Pharmaceutical Preparations
Juridisk Form
XTIQ
ISIN
US1101221083
LEI
HLYYNH7UQUORYSJQCN42
Udbetalingsgrad
54.9%
FCF
11.4 mia. USD
45%
Gæld
43.9 mia. USD
3.1 år FCF
Udbyttestreak
54 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksBMY primærUSD59.12 -0.77%almindelige aktier
LSE London Stock Exchange0R1F IOBGBP—almindelige aktier
MI Borsa Italiana (Milan)1BMY sekundærEUR53.13 +0.28%almindelige aktier
MX Mexican Stock ExchangeBMY sekundærMXN1 047 -3.81%almindelige aktier
VI Vienna Stock ExchangeBMYS sekundærEUR52.98 +0.34%almindelige aktier
XETRA XetraBRM sekundærEUR53.04 +0.89%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, US:BMY: 2.52 USD (4 udb.)

Bristol-Myers Squibb Company (BMY) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 2.52 USD pr. Aktie (betalinger: 4). Det svarer til cirka 4.26% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 01.01.2027. Uafbrudt udbyttehistorik: 54 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-10-022026-11-020.6300 USD1.1/4.3 %kvartalsvisUS:BMY
2026-07-022026-08-030.6300 USD1.1/4.2 %kvartalsvisUS:BMY
2026-04-022026-05-010.6300 USD1.1/4.2 %kvartalsvisUS:BMY
2026-01-022026-02-020.6300 USD1.1/4.2 %kvartalsvisUS:BMY
2025-10-032025-11-030.6200 USD1.0/4.2 %kvartalsvisUS:BMY
2025-07-032025-08-010.6200 USD1.0/4.2 %kvartalsvisUS:BMY
2025-04-042025-05-010.6200 USD1.0/4.1 %kvartalsvisUS:BMY
2025-01-032025-02-030.6200 USD1.0/4.1 %kvartalsvisUS:BMY
2024-10-042024-11-010.6000 USD1.0/4.1 %kvartalsvisUS:BMY
2024-07-052024-08-010.6000 USD1.0/≈4.1 %kvartalsvisUS:BMY
2024-04-042024-05-010.6000 USD1.0/≈4.1 %kvartalsvisUS:BMY
2024-01-042024-02-010.6000 USD1.0/1.0 %kvartalsvisUS:BMY

Nyheder Denne Uge

Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.

annonce

Største Ejere

EjerAndelAktierRapportdato
Blackrock Inc.8.83%180.38 mio.2026-06-30
Vanguard Capital Managem…6.53%133.34 mio.2026-06-30
State Street Corporation5.01%102.41 mio.2026-06-30
JPMORGAN CHASE & CO3.51%71.71 mio.2026-06-30
Charles Schwab Investmen…3.31%67.6 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%64.83 mio.2026-06-30
Geode Capital Management…2.76%56.44 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%52.92 mio.2026-06-30
SCHWAB STRATEGIC TRUST-S…2.38%48.64 mio.2026-05-31
Vanguard Portfolio Manag…2.29%46.87 mio.2026-06-30
NORGES BANK1.8%36.87 mio.2026-06-30
Bank of America Corporat…1.67%34.05 mio.2026-06-30
Price (T.Rowe) Associate…1.55%31.71 mio.2026-06-30
iShares Trust-iShares Co…1.35%27.55 mio.2026-08-31
Fidelity Concord Street…1.29%26.41 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%24.96 mio.2026-08-31
VANGUARD INDEX FUNDS-Van…0.95%19.44 mio.2026-06-30
SELECT SECTOR SPDR TRT-S…0.72%14.68 mio.2026-08-31
VANGUARD CHESTER FUNDS-V…0.7%14.29 mio.2026-06-30
VANGUARD INSTITUTIONAL I…0.54%11.09 mio.2026-06-30
LEUNG SANDRA (General Co…≈0.02%465 3742025-03-10
ELKINS DAVID VINCENT (Ch…≈0.01%159 5422026-04-01
BOERNER CHRISTOPHER S (C…≈0.01%146 8902026-03-10
HIRAWAT SAMIT (Officer)≈0%83 5132025-04-25
HALLER JULIA A (Director…≈0%34 0792026-06-15
MEYERS GREGORY SCOTT (Ch…≈0%30 3612026-03-10
LENKOWSKY ADAM (Officer)≈0%28 6772026-05-01
SHANAHAN KARIN (Officer)≈0%27 3452026-04-01
PLENGE ROBERT M (Officer…≈0%24 7542026-03-10
MASSACESI CRISTIAN (Offi…≈0%18 7482026-09-09